Skip to main content

Amber Moody

Postdoctoral Trainee

Amber Moody



Dr. Moody obtained her PhD in 2018 from the University of Tennessee in Physical Chemistry where her research focused on developing a detection method for biomarkers of neurodegenerative diseases using Raman spectroscopy. She followed this with a postdoctoral fellowship at the FDA primary research facility, the National Center for Toxicological Research (NCTR). At NCTR she used immunohistochemistry to study the toxicity of general anesthesia on the developing brain. She joined the T32 Cancer Nanotechnology program in August 2019 to work under Dr. Paul Dayton and Dr. William Zamboni. Her current research combines pharmacokinetics and ultrasound imaging to modulate the dense tumor matrix in order to increase the tumor delivery and efficacy of nanoparticles.